Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer
Abstract Background Cancer immunotherapies are emerging as promising treatment strategies for ovarian cancer patients that experience disease relapse following first line therapy. As such, identifying strategies to bolster anti-tumor immunity and limit immune suppression, while recognizing diverse p...
Main Authors: | A. J. Robert McGray, Ruea-Yea Huang, Sebastiano Battaglia, Cheryl Eppolito, Anthony Miliotto, Kyle B. Stephenson, Amit A. Lugade, Gill Webster, Brian D. Lichty, Mukund Seshadri, Danuta Kozbor, Kunle Odunsi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40425-019-0641-x |
Similar Items
-
Development and applications of oncolytic Maraba virus vaccines
by: Pol JG, et al.
Published: (2018-11-01) -
Induction of cell death in ovarian cancer cells by doxorubicin and oncolytic vaccinia virus is associated with CREB3L1 activation
by: Anna Mistarz, et al.
Published: (2021-12-01) -
Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors
by: S. Feola, et al.
Published: (2018-08-01) -
Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials
by: Jonathan G. Pol, et al.
Published: (2019-01-01) -
Perspectives on immunotherapy via oncolytic viruses
by: Alberto Reale, et al.
Published: (2019-02-01)